AUTHORS
Chiara Pirillo, PhD, Astraea Jager2, Pablo Domizi, PhD3, Abhishek Vallabhbhai Koladiya, PhD4, Yuxuan Liu, PhD5, Milton Merchant6, Erin H. Breese, MD,PhD7, Rishi S. Kotecha, MB, PhD8, Erin Guest, MD9, Kathrin Bernt, MD10, John A. Kairalla, PhD11, Mignon L. Loh, MD12, David T. Teachey, MD13, Carol Fries Simpson, MD14, Kara L. Davis, D.O.15
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 Stanford University School of Medicine, Stanford, California, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 University of Cincinnati College of Medicine, Cincinnati, OH; Division of Oncology, Blood and Cancer Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, Ohio, United States
8 Perth Children's Hospital, Perth, Western Australia, Australia
9 Children’s Mercy Kansas City, Kansas City, Missouri, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 University of Florida, Gainesville, Florida, United States
12 Seattle Children’s Hospital, and Fred Hutch Cancer Center, University of Washington, Seattle, Washington, United States
13 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
14 University of Rochester, Rochester, New York, United States
15 Stanford University School of Medicine, Stanford, California, United States
ABSTRACT
Infant KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2Ar iALL) remains the highest-risk pediatric ALL subtype, with a historical five-year event-free survival below 40% and relapse as the primary cause of treatment failure. Despite the emergence of targeted therapies, the leukemic cell states that survive therapy and drive relapse remain poorly understood. To identify relapse-inducing cell populations, we performed multimodal single-cell profiling of primary infant KMT2Ar iALL samples from the COG AALL15P1 cohort (n=33) using Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq; n=25, 38 surface proteins) with paired V(D)J sequencing, together with complementary cytometry by time-of-flight (CyTOF; n=33, 43 surface and intracellular proteins) profiling.
Across all analyzed patients, transcriptomic analyses identified a conserved leukemic population characterized by coordinated expression of SOX4, SOCS2, and CDK6, termed SSC-high cells. SSC-high cells exhibited significantly elevated stemness scores relative to SSC-low cells (paired Wilcoxon p=0.008), together with increased expression of MSI2 (paired Wilcoxon p=0.017), an RNA-binding protein implicated in leukemia stem cell maintenance, glucocorticoid resistance, and poor clinical outcome in B-ALL. Importantly, SSC-high cells remained detectable in all 4 paired relapse samples, with expansion observed in 3 of 4 cases, indicating persistence and enrichment under therapeutic pressure. Consistent with this observation, clonal tracking using paired diagnosis-relapse V(D)J transcriptomic sequencing (n=4) demonstrated that diagnostic clonotypes containing SSC-high cells were markedly enriched among relapse-persistent clones compared with clonotypes lacking SSC-high representation (32.6% versus 3.3% by heavy-chain clonotype and 29.5% versus 2.9% by paired heavy-light chain clonotype), representing approximately a 10-fold enrichment.
SSC-high cells further exhibited reduced glycolytic (p=0.018), mTORC1 (p=0.007), and oxidative phosphorylation activity (p=0.002), consistent with a metabolically quiescent, therapy-tolerant phenotype. Gene set enrichment analysis demonstrated enrichment of stress-adaptation pathways, including TNFA signaling via NFκB, hypoxia, and reactive oxygen species. Integrated transcriptomic and surface protein profiling identified a distinct molecular and immunophenotypic signature of SSC cells nominating candidate markers for their prospective enrichment. Developmental mapping and complementary CyTOF analysis demonstrated that KMT2Ar infant ALL comprises developmentally heterogeneous leukemic populations spanning multiple stages of early B-cell differentiation. Within this landscape, SSC-high cells localized predominantly to the Pro-B VDJ and Early Progenitor compartments, consistent with their immature B-cell phenotype. Ongoing studies are evaluating the leukemia-propagating potential of isolated SSC-high cells in PDX models, their response to targeted therapies, and integrating clinical Ig-HTS clonotype tracking with single-cell V(D)J-defined SSC-high states to determine how these populations contribute to disease evolution and relapse.
Together, these findings identify SSC-high as a conserved stem-like leukemic state defined by developmental immaturity, metabolic quiescence, and clonal persistence at relapse, nominating it as a potential reservoir of treatment failure and a priority target for therapeutic investigation in KMT2Ar iALL.
DISCLOSURES
Chiara Pirillo, PhD: No relevant conflicts of interest to declare.